{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T11:21:50Z","timestamp":1787829710873,"version":"build-2784847793"},"reference-count":51,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Myelination, mitochondrial bioenergetics, and oxidative stress are usually discussed as separate problems in optic nerve disease. This review draws them together and reads the published evidence through a single variable, the balance between the energy a retinal ganglion cell (RGC) axon spends and the energy its mitochondria can supply. We review the role of myelin in conduction and axonal support, the mitochondrial cost of building and maintaining it, the vulnerability of oligodendrocytes and myelin to oxidative injury, and the nuclear control of mitochondrial output. We summarize the inherited optic atrophies linked to OPA1, OPA3, AFG3L2, SPG7, and TMEM126A, and set these primary mitochondrial disorders against the immune-mediated demyelinating optic neuropathies. Published studies already support several parts of this picture, including the energetic cost of demyelination, the mitochondrial dependence of RGC axons, and oxidative injury in inflammatory lesions. Drawing on that evidence, we propose, as a testable hypothesis rather than a settled mechanism, that optic nerve degeneration is favored when axonal ATP demand outruns mitochondrial supply, most sharply where the axon crosses from its unmyelinated to its myelinated segment near the lamina cribrosa. We use this framework to separate initiating lesions from disease modifiers and downstream consequences, and to set out therapeutic predictions open to experimental and clinical tests.<\/jats:p>","DOI":"10.3390\/ijms27177678","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:58:21Z","timestamp":1787828301000},"page":"7678","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mitochondrial Control of Myelination, Bioenergetics, Oxidative Stress, and the Pathogenesis of Optic Neuropathies"],"prefix":"10.3390","volume":"27","author":[{"given":"Haya","family":"Sahibzada","sequence":"first","affiliation":[{"name":"Research Department, King Khaled Eye Specialist Hospital and Research Center, Riyadh 11462, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan","family":"Malik","sequence":"additional","affiliation":[{"name":"Research Department, King Khaled Eye Specialist Hospital and Research Center, Riyadh 11462, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled K.","family":"Abu-Amero","sequence":"additional","affiliation":[{"name":"Research Department, King Khaled Eye Specialist Hospital and Research Center, Riyadh 11462, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-cellbio-100913-013101","article-title":"Myelination of the nervous system: Mechanisms and functions","volume":"30","author":"Nave","year":"2014","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Yang, T.-H., Kang, E.Y.-C., Lin, P.-H., Yu, B.B.-C., Wang, J.H.-H., Chen, V., and Wang, N.-K. (2024). Mitochondria in retinal ganglion cells: Unraveling the metabolic nexus and oxidative stress. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25168626"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.preteyeres.2003.10.003","article-title":"Mitochondrial dysfunction as a cause of optic neuropathies","volume":"23","author":"Carelli","year":"2004","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_4","first-page":"1","article-title":"Myelination and regional domain differentiation of the axon","volume":"48","author":"Thaxton","year":"2009","journal-title":"Results Probl. Cell Differ."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.conb.2013.09.008","article-title":"The role of myelin and oligodendrocytes in axonal energy metabolism","volume":"23","author":"Saab","year":"2013","journal-title":"Curr. Opin. Neurobiol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Stassart, R.M., Mobius, W., Nave, K.A., and Edgar, J.M. (2018). The axon-myelin unit in development and degenerative disease. Front. Neurosci., 12.","DOI":"10.3389\/fnins.2018.00467"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Meyer, N., and Rinholm, J.E. (2021). Mitochondria in myelinating oligodendrocytes: Slow and out of breath?. Metabolites, 11.","DOI":"10.3390\/metabo11060359"},{"key":"ref_8","first-page":"100360","article-title":"Myelin lipid metabolism and its role in myelination and myelin maintenance","volume":"4","author":"Hu","year":"2022","journal-title":"Innovation (Camb)"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/glia.20496","article-title":"IGF-1 stimulates de novo fatty acid biosynthesis by Schwann cells during myelination","volume":"55","author":"Liang","year":"2007","journal-title":"Glia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nature11007","article-title":"Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity","volume":"485","author":"Funfschilling","year":"2012","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1002\/jnr.22139","article-title":"Oxidative stress disrupts oligodendrocyte maturation","volume":"87","author":"French","year":"2009","journal-title":"J. Neurosci. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-3-319-40764-7_8","article-title":"Oligodendrocytes: Functioning in a delicate balance between high metabolic requirements and oxidative damage","volume":"949","author":"Roth","year":"2016","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1007\/s00018-021-03802-0","article-title":"Oxidative stress and impaired oligodendrocyte precursor cell differentiation in neurological disorders","volume":"78","author":"Spaas","year":"2021","journal-title":"Cell Mol. Life Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102118","DOI":"10.1016\/j.redox.2021.102118","article-title":"Ceruloplasmin deletion in myelinating glial cells induces myelin disruption and oxidative stress in the central and peripheral nervous systems","volume":"46","author":"Cheli","year":"2021","journal-title":"Redox Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/(SICI)1098-1136(20000115)29:2<124::AID-GLIA5>3.0.CO;2-O","article-title":"Cell death in the oligodendrocyte lineage: A molecular perspective of life and death decisions in development and disease","volume":"29","year":"2000","journal-title":"Glia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1515\/hsz-2013-0152","article-title":"The nuclear receptor peroxisome proliferator-activated receptor-\u03b3 promotes oligodendrocyte differentiation through mechanisms involving mitochondria and oscillatory Ca2+ waves","volume":"394","author":"Bernardo","year":"2013","journal-title":"Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/glia.23905","article-title":"Mitochondrial dynamics and bioenergetics regulated by netrin-1 in oligodendrocytes","volume":"69","author":"Nakamura","year":"2021","journal-title":"Glia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1007\/s00018-021-03775-0","article-title":"Mitochondrial quality control: From molecule to organelle","volume":"78","author":"Tait","year":"2021","journal-title":"Cell Mol. Life Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.bbamcr.2006.04.003","article-title":"Mitochondrial dynamics and disease, OPA1","volume":"1763","author":"Olichon","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/hmg\/10.13.1359","article-title":"OPA1 mutations in patients with autosomal dominant optic atrophy and evidence for semi-dominant inheritance","volume":"10","author":"Pesch","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ymgme.2010.03.005","article-title":"OPA3, mutated in 3-methylglutaconic aciduria type III, encodes two transcripts targeted primarily to mitochondria","volume":"100","author":"Huizing","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1750-3639.1999.tb00212.x","article-title":"Demyelination: The role of reactive oxygen and nitrogen species","volume":"9","author":"Smith","year":"1999","journal-title":"Brain Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/glia.22597","article-title":"Mechanisms of white matter damage in multiple sclerosis","volume":"62","author":"Lassmann","year":"2014","journal-title":"Glia"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/brain\/aws012","article-title":"NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury","volume":"135","author":"Fischer","year":"2012","journal-title":"Brain"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/brain\/awr128","article-title":"Oxidative damage in multiple sclerosis lesions","volume":"134","author":"Haider","year":"2011","journal-title":"Brain"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"708659","DOI":"10.1155\/2013\/708659","article-title":"Immunology and oxidative stress in multiple sclerosis: Clinical and basic approach","volume":"2013","author":"Ortiz","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nm.2324","article-title":"A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"17","author":"Nikic","year":"2011","journal-title":"Nat. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Kumar, V., and Jurkunas, U.V. (2021). Mitochondrial dysfunction and mitophagy in Fuchs endothelial corneal dystrophy. Cells, 10.","DOI":"10.3390\/cells10081888"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1350-9462(98)00026-3","article-title":"Differential gene expression in the human ciliary epithelium","volume":"18","author":"Escribano","year":"1999","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1098\/rstb.2010.0302","article-title":"Biological glass: Structural determinants of eye lens transparency","volume":"366","author":"Bassnett","year":"2011","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/EB.S16192","article-title":"Mitochondrial disorders and the eye","volume":"3","author":"Trounce","year":"2011","journal-title":"Eye Brain"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Carrella, S., Massa, F., and Indrieri, A. (2021). The role of microRNAs in mitochondria-mediated eye diseases. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.653522"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"6435364","DOI":"10.1155\/2019\/6435364","article-title":"Mitochondria as potential targets and initiators of the blue light hazard to the retina","volume":"2019","author":"Tao","year":"2019","journal-title":"Oxid. Med. Cell Longev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.mito.2016.08.016","article-title":"Immunolocalisation pattern of complex I-V in ageing human retina: Correlation with mitochondrial ultrastructure","volume":"31","author":"Nag","year":"2016","journal-title":"Mitochondrion"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/B978-0-12-821751-1.00010-5","article-title":"Mitochondrial optic neuropathies","volume":"194","author":"Carelli","year":"2023","journal-title":"Handb. Clin. Neurol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40478-020-00975-w","article-title":"A novel AFG3L2 mutation close to the AAA domain leads to aberrant OMA1 and OPA1 processing in a family with optic atrophy","volume":"8","author":"Baderna","year":"2020","journal-title":"Acta. Neuropathol. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1212\/NXG.0000000000000428","article-title":"Mutations in the m-AAA proteases AFG3L2 and SPG7 are causing isolated dominant optic atrophy","volume":"6","author":"Charif","year":"2020","journal-title":"Neurol. Genet."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ajhg.2009.03.003","article-title":"TMEM126A, encoding a mitochondrial protein, is mutated in autosomal-recessive nonsyndromic optic atrophy","volume":"84","author":"Hanein","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/nyas.12794","article-title":"Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: A decade later","volume":"1366","author":"Pittock","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e786","DOI":"10.1097\/WNO.0000000000001234","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis: A review","volume":"41","author":"Kaushik","year":"2021","journal-title":"J. Neuroophthalmol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/ana.22166","article-title":"Charcot-Marie-Tooth disease subtypes and genetic testing strategies","volume":"69","author":"Saporta","year":"2011","journal-title":"Ann. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/mgg3.106","article-title":"The allelic spectrum of Charcot-Marie-Tooth disease in over 17,000 individuals with neuropathy","volume":"2","author":"DiVincenzo","year":"2014","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/B978-0-444-64076-5.00045-4","article-title":"Neurogenetics of Pelizaeus-Merzbacher disease","volume":"148","author":"Osorio","year":"2018","journal-title":"Handb. Clin. Neurol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1194\/jlr.R009761","article-title":"Lipid metabolism in myelinating glial cells: Lessons from human inherited disorders and mouse models","volume":"52","author":"Chrast","year":"2011","journal-title":"J. Lipid Res."},{"key":"ref_45","unstructured":"Cohen, B.H., Chinnery, P.F., and Copeland, W.C. (2010). POLG-Related Disorders. GeneReviews, University of Washington. updated 2024."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"106467","DOI":"10.1016\/j.nbd.2024.106467","article-title":"Charcot-Marie-Tooth disease type 2A: An update on pathogenesis and therapeutic perspectives","volume":"194","author":"Alberti","year":"2024","journal-title":"Neurobiol. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/01658107.2023.2251575","article-title":"Idebenone treatment in patients with OPA1-dominant optic atrophy: A prospective phase 2 trial","volume":"47","author":"Valentin","year":"2023","journal-title":"Neuroophthalmology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","article-title":"Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): A randomised, controlled, double-blind, crossover trial","volume":"390","author":"Green","year":"2017","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e076651","DOI":"10.1136\/bmjopen-2023-076651","article-title":"Measuring and predicting the effect of remyelinating therapy in multiple sclerosis: A randomised controlled trial protocol (RESTORE)","volume":"14","author":"Hof","year":"2024","journal-title":"BMJ Open"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1186\/s13063-025-09254-2","article-title":"The Cambridge Centre for Myelin Repair trial Two (CCMR Two): A trial protocol for a phase 2a, randomised, double-blind, placebo-controlled clinical trial of the ability of the combination of metformin and clemastine to promote remyelination in people with relapsing-remitting multiple sclerosis already on disease-modifying therapy","volume":"26","author":"McMurran","year":"2025","journal-title":"Trials"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e183941","DOI":"10.1172\/JCI183941","article-title":"Clemastine fumarate accelerates accumulation of disability in progressive multiple sclerosis by enhancing pyroptosis","volume":"135","author":"Kocot","year":"2025","journal-title":"J. Clin. Investig."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7678\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:59:47Z","timestamp":1787828387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":51,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27177678"],"URL":"https:\/\/doi.org\/10.3390\/ijms27177678","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]}}}